Intelligent Bio-Orthogonal Drug Activation Systems
Legal Citation
Summary of the Inventive Concept
A novel approach to bio-orthogonal drug activation by integrating AI, IoT, blockchain, and nanomaterials to create personalized, targeted, and efficient treatment systems.
Background and Problem Solved
The original patent on bio-orthogonal drug activation using retro Diels-Alder reactions has limitations in terms of targeted delivery, real-time monitoring, and secure data management. The new inventive concept addresses these limitations by incorporating AI-powered diagnostic modules, IoT-enabled wearable devices, blockchain-based patient data management systems, and nanomaterial-based prodrug delivery systems.
Detailed Description of the Inventive Concept
The new inventive concept comprises a bio-orthogonal drug activation module, an AI-powered diagnostic module, and a blockchain-based patient data management system. The bio-orthogonal drug activation module uses a retro Diels-Alder reaction to activate a prodrug. The AI-powered diagnostic module analyzes patient data stored in the blockchain-based patient data management system to optimize prodrug activation. The system can be integrated with IoT-enabled wearable devices for real-time monitoring and machine learning-based predictive analytics for optimal treatment outcomes.
Novelty and Inventive Step
The new claims introduce the innovative combination of AI, IoT, blockchain, and nanomaterials with bio-orthogonal drug activation, enabling personalized, targeted, and efficient treatment systems. This integration is not obvious from the original patent and provides a significant advancement in the field.
Alternative Embodiments and Variations
Alternative embodiments may include the use of different AI algorithms, various IoT devices, or alternative blockchain platforms. The inventive concept can also be adapted for different types of prodrugs, diseases, or treatment modalities.
Potential Commercial Applications and Market
The intelligent bio-orthogonal drug activation systems have vast commercial potential in the pharmaceutical, biotechnology, and healthcare industries. The market for targeted and personalized medicine is growing rapidly, and this inventive concept is poised to revolutionize the field with its innovative approach to bio-orthogonal drug activation.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K47/6803 |
| A | A61 | A61K31/435 |
| A | A61 | A61K31/444 |
| A | A61 | A61K31/704 |
| A | A61 | A61K38/05 |
| A | A61 | A61K39/3955 |
| A | A61 | A61K39/39558 |
| A | A61 | A61K47/22 |
| A | A61 | A61K47/545 |
| A | A61 | A61K47/555 |
| A | A61 | A61K47/558 |
| A | A61 | A61K47/6897 |
| B | B82 | B82Y5/00 |
| C | C07 | C07C33/16 |
| C | C07 | C07D237/26 |
| C | C07 | C07D257/08 |
| Y | Y02 | Y02A50/30 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical biotechnology, drug delivery systems, and bio-orthogonal chemical reactions, with expertise in prodrug activation, targeted drug delivery, and advanced computational methods for personalized medicine
Person of Ordinary Skill (PHOSITA) Profile
A researcher with advanced degrees in pharmaceutical sciences, biochemistry, or biomedical engineering, possessing knowledge of drug design, chemical modification techniques, computational biology, and emerging technologies in personalized medicine
Obviousness Rationale
A PHOSITA would recognize that integrating computational technologies with bio-orthogonal drug activation represents a natural progression in personalized medicine. The combination of AI, blockchain, and IoT with existing prodrug activation techniques follows established trends in precision healthcare technology. The technical elements disclosed in the PTD represent predictable extensions of known methodologies in drug delivery and computational healthcare systems.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,636 |
|---|---|
| Title | Bio-orthogonal drug activation |
| Assignee(s) | Tagworks Pharmaceuticals B.V. |